Robert Schwartz

Investment Research and Analysis - Drug Development Consulting - Asset and company searches - Technical evaluations and diligence - Financial evaluations including forecasting, P&L development and DCFs - Competitive landscape assessments and SWOT analyses - Deal-terms development and modeling - Technical meeting coverage - Operational support/guidance About Robert Schwartz Dr. Robert Schwartz is a 30-year veteran of the pharmaceutical industry with broad-based experience in drug development and commercialization. He began his career in 1979 as a research chemist at Ciba-Geigy Corporation (9 + years) and then joined E.R. Squibb & Sons in 1989 where he was responsible for coordinating the non-clinical development of the company’s pipeline assets. In July 1997, Robert joined Bristol-Myers Squibb’s (BMS’) U.S. Oncology business where he was responsible for new business ventures and life-cycle management. He transitioned to BMS’ Licensing and Business Development (later Strategic Transactions) group in 2002 where he was credited with rebuilding the company’s oncology pipeline. Dr. Schwartz is perhaps best known for predicting FDA’s rejection of Dendreon’s Provenge vaccine in 2007 (San Francisco Chronicle, March 30, 2007). Provenge ultimately won FDA approval in April, 2010.

ILMN, MDVN, ONXX, VRTX. We established a short position in CLSN on 1/13/2013 which we have since closed. Our YTD return through 4/12/2013 is 27.5%.